Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Colorectal Cancer Reports
Published in: Current Colorectal Cancer Reports 2/2013

01-06-2013 | Localized Rectal Cancer (R Glynne-Jones, Section Editor)

Quality of Life and Functions After Chemoradiation for Rectal Cancer: A Review of Recent Publications

Authors: Teresa Gavaruzzi, Francesca Giandomenico, Salvatore Pucciarelli

Published in: Current Colorectal Cancer Reports | Issue 2/2013

Login to get access

Abstract

We have systematically reviewed studies published in the last three years on patients’ self-reported evaluations of quality of life (QoL) and functions after chemoradiotherapy (CRT) for rectal cancer. Overall, the findings from 13 studies confirmed that CRT negatively affect functions and, consequently, patients’ QoL, especially for bowel, role, and social function. The studies’ heterogeneity limited the possibility of comparison among findings. We discuss and comment on the ideal characteristics of studies assessing QoL and function. We emphasise how this type of evidence is relevant to decision-making at all levels of health-care practice.
Literature
1.
Kosinski L, Habr-Gama A, Ludwig K, Perez R. Shifting concepts in rectal cancer management a review of contemporary primary rectal cancer treatment strategies. CA Cancer J Clin. 2012;62(3):173–202.PubMedCrossRef
2.
Palmer G, Martling A, Cedermark B, Holm T. Preoperative tumour staging with multidisciplinary team assessment improves the outcome in locally advanced primary rectal cancer. Colorectal Dis. 2011;13(12):1361–9.PubMedCrossRef
3.
Burton S, Brown G, Daniels IR, et al. MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins? Br J Cancer. 2006;94(3):351–7.PubMedCrossRef
4.
Blazeby JM, Avery K, Sprangers M, et al. Health-related quality of life measurement in randomized clinical trials in surgical oncology. J Clin Oncol. 2006;24(19):3178–86.PubMedCrossRef
5.
Langenhoff BS, Krabbe PF, Wobbes T, et al. Quality of life as an outcome measure in surgical oncology. Br J Surg. 2001;88(5):643–52.PubMedCrossRef
6.
Lipscomb J, Gotay C, Snyder C. Introduction to outcome assessment in cancer. In: Outcomes assessment in cancer: measures, methods and applications. Cambridge: Cambridge University Press; 2005. p. 11–3.
7.
• Hadi M, Gibbons E, Fitzpatrick R. A structured review of patient-reported outcome measures for colorectal cancer. Patient-reported Outcome Measurement Group, Department of Public Health, University of Oxford April 2010. Review of the evidence of PROs for colorectal cancer patients, distinguishing between generic, preference-based, and cancer-specific instruments.
8.
Snyder C, Aaronson NK. Use of patient-reported outcomes in clinical practice. Lancet. 2009;374(9687):369–70.PubMedCrossRef
9.
Donaldson MS. Taking PROs and patient-centered care seriously: incremental and disruptive ideas for incorporating PROs in oncology practice. Qual Life Res. 2008;17(10):1323–30.PubMedCrossRef
10.
Pieterse AH, Baas-Thijssen MC, Marijnen CA, Stiggelbout AM. Clinician and cancer patient views on patient participation in treatment decision-making: a quantitative and qualitative exploration. Br J Cancer. 2008;99(6):875–82.PubMedCrossRef
11.
Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40.PubMedCrossRef
12.
Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–33.PubMedCrossRef
13.
Bosset J-F, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114–23.PubMedCrossRef
14.
Gérard J-P, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancer: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620–5.PubMedCrossRef
15.
Engel J, Kerr J, Schleisinger-Racib A, et al. Quality of life in rectal cancer patients: a four-year prospective study. Ann Surg. 2003;238(2):203–13.PubMed
16.
Neuman HB, Schrag D, Cabral C, et al. Can differences in bowel function after surgery for rectal cancer be identified by the European Organization for Research and Treatment of Cancer quality of life instruments? Ann Surg Oncol. 2007;14(5):1727–34.PubMedCrossRef
17.
Pietrzak L, Mujko K, Novacki MP, et al. Quality of life, anorectal and sexual functions after preoperative radiotherapy for rectal cancer: report of a randomized trial. Radiother Oncol. 2007;84(3):217–25.PubMedCrossRef
18.
Pucciarelli S, Del Bianco P, Efficace F, et al. Health-related quality of life, faecal continence and bowel function in rectal cancer patients after chemoradiotherapy followed by radical surgery. Support Care Cancer. 2010;18(5):601–8.PubMedCrossRef
19.
Rauch P, Miny J, Conroy T, et al. Quality of life among disease-free survivors of rectal cancer. J Clin Oncol. 2004;22(2):354–60.PubMedCrossRef
20.
Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. J Clin Oncol. 2005;23:6199–206.PubMedCrossRef
21.
• Brændengen M, Tveit KM, Hjermstad MJ, et al. Health-related quality of life (HRQoL) after multimodal treatment for primarily non-resectable rectal cancer. Long-term results from a phase III study. Eur J Cancer. 2012;48(6):813–9. Prospective evaluation of QoL in a randomised trial, comparing pCRT and pRT and comparing results also with reference data from the general population.PubMedCrossRef
22.
Brændengen M, Tveit KM, Bruheim K, et al. Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized phase III study. Int J Radiat Oncol Biol Phys. 2011;81(4):1017–24.PubMedCrossRef
23.
•• Kang SB, Park JW, Jeong SY, et al. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of a open-label randomised controlled trial. Lancet Oncol. 2010;11(7):637–45. Prospective evaluation of QoL in a randomised trial comparing laparoscopic and open TME. Prospective study with high compliance and adequate sample size.PubMedCrossRef
24.
Stephens RJ, Thompson LC, Quirke P, et al. Impact of short-course preoperative radiotherapy for rectal cancer on patients’ quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial. J Clin Oncol. 2010;27:4233–9.CrossRef
25.
Tiv M, Puyraveau M, Mineur L, et al. Long-term quality of life in patients with rectal cancer treated with preoperative (chemo)-radiotherapy within a randomized trial. Cancer Radiother. 2010;14(6–7):530–4.PubMedCrossRef
26.
Canda AE, Terzi C, Gorken IB, et al. Effects of preoperative chemoradiotherapy on anal sphincter functions and quality of life in rectal cancer patients. Int J Colorectal Dis. 2010;25(2):197–204.PubMedCrossRef
27.
How P, Stelzner S, Branagan G, et al. Comparative Quality of life in patients following abdominoperineal excision and low anterior resection for low rectal cancer. Dis Colon Rectum. 2012;55(4):400–6.PubMedCrossRef
28.
Kripp M, Wieneke J, Kienle P, et al. Intensified neoadjuvant chemoradiotherapy in locally advanced rectal cancer – impact on long-term quality of life. Eur J Surg Oncol. 2012;38(6):472–7.PubMedCrossRef
29.
Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29(35):4633–40.PubMedCrossRef
30.
Nishizawa Y, Fujii S, Saito N, et al. The association between anal function and neural degeneration after preoperative chemoradiotherapy followed by intersphinteric resection. Dis Colon Rectum. 2011;54(11):1423–9.PubMedCrossRef
31.
Peng J, Shi D, Goodman KA, et al. Early results of quality of life for curatively treated rectal cancer in Chinese patients with EORTC QLQ-CR29. Radiat Oncol. 2011;6:93.PubMedCrossRef
32.
Lupattelli M, Mascioni F, Bellavita R, et al. Long-term anorectal function after postoperative chemoradiotherapy in high-risk rectal cancer patients. Tumori. 2010;96(1):34–41.PubMed
33.
•• Pucciarelli S, Del Bianco P, Efficace F, et al. Patient-Reported outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a multicenter prospective observational study. Ann Surg. 2011;253(1):71–7. Prospective and multicentre evaluation of QoL, with several assessments, including at baseline, high compliance, and large sample size, focused on the effect of CRT treatment on QoL.PubMedCrossRef
34.
Aaronson NK, Ahmedzai S, Bergam B, et al. European Organisation for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.PubMedCrossRef
35.
Sprangers M, Te Velde A, Aaronson N. The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module. (QLQ-CR38). Eur J Cancer. 1999;35(2):238–47.PubMedCrossRef
36.
Whistance RN, Conroy T, Chie W, et al. European Organisation for research and treatment of Cancer Quality of Life Group. Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer. Eur J Cancer. 2009;45(17):3017–26.PubMedCrossRef
37.
Rockwood TH, Church JM, Fleshman JW, et al. Fecal incontinence quality of life scale: quality of life instrument for patients with fecal incontinence. Dis Colon Rectum. 2000;43(1):9–16.PubMedCrossRef
38.
Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.PubMedCrossRef
39.
Prieto L, Thorsen H, Juul K. Development and validation of a quality of life questionnaire for patients with colostomy or ileostomy. Health Qual Life Outcomes. 2005;3:62.PubMedCrossRef
40.
Jorge JM, Wexner SD. Etiology and management of fecal incontinence. Dis Colon Rectum. 1993;36(1):77–97.PubMedCrossRef
41.
Vaizey CJ, Carapeti E, Cahill JA, Kamm MA. Prospective comparison of faecal incontinence grading systems. Gut. 1999;44(1):77–80.PubMedCrossRef
42.
Temple LK, Bacik J, Savatta SG, et al. The development of a validated instrument to evaluate bowel function after sphincter-preserving surgery for rectal cancer. Dis Colon Rectum. 2005;48(7):1353–65.PubMedCrossRef
43.
Rosen RC, Riley A, Wagner G, Osterloh IH, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822–30.PubMedCrossRef
44.
Jensen PT, Klee M, Thranov I, Groenvold M. Validation of a questionnaire for self-assessment of sexual function and vaginal changes after gynaecological cancer. Psychooncology. 2004;13(8):577–92.PubMedCrossRef
45.
Brændengen M, Tveit KM, Berglund Å, et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol. 2008;26(22):3687–94.PubMedCrossRef
46.
Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373(9666):811–20.PubMedCrossRef
47.
Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal effect of chemotherapy with preoperative radio- therapy for rectal cancer: preliminary results EORTC 22921. J Clin Oncol. 2005;23(24):5620–7.PubMedCrossRef
48.
Bosset JF, Calais G, Daban A, et al. Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance: Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group. Eur J Cancer. 2004;40(2):219–24.PubMedCrossRef
49.
Willeke F, Horisberger K, Kraus-Tiefenbacher U, et al. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer. 2007;96(6):912–7.PubMedCrossRef
50.
Horisberger K, Treschl A, Mai S, et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a phase II MARGIT trial. Int J Radiation Oncology Biol Phys. 2009;74(5):1487–93.CrossRef
51.
Hofheinz R, Wenz F, Post S, et al. Capecitabine (cape) versus 5-fluorouracil (5-FU)-based (neo-)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): safety results of a randomized, phase III trial. J Clinical Oncol. 2009;27(15S):4014.
52.
Holzer B, Matzel K, Schiedeck T, et al. Do geographic and educational factors influence the quality of life in rectal cancer patients with a permanent colostomy? Dis Col Rectum. 2005;48(12):2209–16.CrossRef
53.
Cornish JA, Tilney HS, Heriot AG, et al. A meta-analysis of quality of life for abdominoperineal excision of rectum versus anterior resection for rectal cancer. Ann Surg Oncol. 2007;14(7):2056–68.PubMedCrossRef
54.
Holzer B, Gyasi A, Schiessel R, Rosen HR. Patients’ expectations of colorectal surgery for cancer. Colorectal Dis. 2006;8(3):186–91.PubMedCrossRef
55.
Amsterlaw J, Zikmund-Fisher BJ, Fagerlin A, Ubel PA. Can avoidance of complications lead to biased healthcare decisions? Judgment and Decision Making. 2006;1(1):64–75.
56.
Bossema A, Stiggelbout A, Baas-Thijssen M, et al. Patients’ preferences for low rectal cancer surgery. Eur J Surg Oncol. 2008;34(1):42–8.PubMedCrossRef
57.
Masya L, Young J, Solomon M, et al. Preferences for outcomes of treatment for rectal cancer: patient and clinician utilities and their application in an interactive computer-based decision aid. Dis Colon Rectum. 2009;52(12):1994–2002.PubMedCrossRef
58.
Vironen J, Kairaluoma M, Aalto A, Kellokumpu I. Impact of functional results on quality of life after rectal cancer surgery. Dis Colon Rectum. 2006;49(5):568–78.PubMedCrossRef
59.
Sutherland HJ, Till JE. Quality of life assessments and levels of decision making: differentiating objectives. Qual Life Res. 1993;2(4):297–303.PubMedCrossRef
60.
Stiggelbout AM, de Haes JCJM. Patient preference for cancer therapy: an overview of measurement approaches. J Clin Oncol. 2001;19(1):220–30.PubMed
Metadata
Title
Quality of Life and Functions After Chemoradiation for Rectal Cancer: A Review of Recent Publications
Authors
Teresa Gavaruzzi
Francesca Giandomenico
Salvatore Pucciarelli
Publication date
01-06-2013
Publisher
Current Science Inc.
Published in
Current Colorectal Cancer Reports / Issue 2/2013
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-013-0161-x

Other articles of this Issue 2/2013

Current Colorectal Cancer Reports 2/2013 Go to the issue

Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

The ALPPS Approach for the Management of Colorectal Carcinoma Liver Metastases

Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

Irreversible Electroporation: a Novel Option for Treatment of Hepatic Metastases

Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

Management of the Hepatic Lymph Nodes During Resection of Liver Metastases from Colorectal Cancer: A Systematic Review

Localized Rectal Cancer (R Glynne-Jones, Section Editor)

How Could the TNM System Be Best Adapted for Staging Rectal Cancer in the Future?

Localized Rectal Cancer (R Glynne-Jones, Section Editor)

Colorectal Cancer in the Elderly: How Do We Tailor Treatment with Chemotherapy and Radiotherapy Most Appropriately?

Localized Rectal Cancer (R Glynne-Jones, Section Editor)

The Role of Enhanced Recovery After Surgery for Rectal Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits